ATE317389T1 - 4-phenyl-pyrimidine derivate - Google Patents

4-phenyl-pyrimidine derivate

Info

Publication number
ATE317389T1
ATE317389T1 AT00927234T AT00927234T ATE317389T1 AT E317389 T1 ATE317389 T1 AT E317389T1 AT 00927234 T AT00927234 T AT 00927234T AT 00927234 T AT00927234 T AT 00927234T AT E317389 T1 ATE317389 T1 AT E317389T1
Authority
AT
Austria
Prior art keywords
phenyl
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
AT00927234T
Other languages
English (en)
Inventor
Michael Boes
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE317389T1 publication Critical patent/ATE317389T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00927234T 1999-05-31 2000-05-24 4-phenyl-pyrimidine derivate ATE317389T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99110483 1999-05-31

Publications (1)

Publication Number Publication Date
ATE317389T1 true ATE317389T1 (de) 2006-02-15

Family

ID=8238271

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927234T ATE317389T1 (de) 1999-05-31 2000-05-24 4-phenyl-pyrimidine derivate

Country Status (36)

Country Link
US (1) US6274588B1 (de)
EP (1) EP1187815B1 (de)
JP (1) JP3590592B2 (de)
KR (1) KR100440106B1 (de)
CN (1) CN1166643C (de)
AR (1) AR024146A1 (de)
AT (1) ATE317389T1 (de)
AU (1) AU770786B2 (de)
BR (1) BR0011127A (de)
CA (1) CA2375671C (de)
CO (1) CO5170520A1 (de)
CZ (1) CZ20014271A3 (de)
DE (1) DE60025918T2 (de)
DK (1) DK1187815T3 (de)
ES (1) ES2257294T3 (de)
GC (1) GC0000191A (de)
HK (1) HK1046528B (de)
HR (1) HRP20010871A2 (de)
HU (1) HUP0201315A3 (de)
IL (2) IL146460A0 (de)
JO (1) JO2261B1 (de)
MA (1) MA26793A1 (de)
MX (1) MXPA01012089A (de)
MY (1) MY122731A (de)
NO (1) NO321354B1 (de)
NZ (1) NZ515407A (de)
PE (1) PE20010153A1 (de)
PL (1) PL353441A1 (de)
PT (1) PT1187815E (de)
RU (1) RU2243221C2 (de)
SI (1) SI1187815T1 (de)
TR (1) TR200103457T2 (de)
TW (1) TW550258B (de)
WO (1) WO2000073279A1 (de)
YU (1) YU84901A (de)
ZA (1) ZA200109163B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP4623354B2 (ja) * 2000-09-14 2011-02-02 味の素株式会社 新規ピリミジン誘導体及び新規ピリジン誘導体
CZ20032233A3 (cs) * 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
EP1809290A2 (de) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidinderivate als ionenkanalmodulatoren und verwendungsverfahren
ES2329827T3 (es) * 2005-02-22 2009-12-01 F. Hoffmann-La Roche Ag Antagonistas de nk1.
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
EA015890B1 (ru) * 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
AU2008355098B2 (en) 2008-04-21 2012-11-15 Gpcr Therapeutics, Inc Heterocyclic compounds
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
WO2016120355A2 (en) * 2015-01-30 2016-08-04 Basf Se Herbicidal phenylpyrimidines
AU2018208366B2 (en) * 2017-01-10 2020-12-17 National Health Research Institutes Heterocyclic compounds and use thereof
KR102006547B1 (ko) * 2017-11-16 2019-08-01 서울대학교산학협력단 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
AR208171A1 (es) * 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
DE3614060A1 (de) * 1986-04-23 1987-10-29 Schering Ag Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
PE20010153A1 (es) 2001-02-08
SI1187815T1 (sl) 2006-06-30
NO321354B1 (no) 2006-05-02
CN1166643C (zh) 2004-09-15
AU4567700A (en) 2000-12-18
TR200103457T2 (tr) 2002-04-22
US6274588B1 (en) 2001-08-14
HK1046528A1 (en) 2003-01-17
DE60025918D1 (de) 2006-04-20
JP3590592B2 (ja) 2004-11-17
EP1187815A1 (de) 2002-03-20
CZ20014271A3 (cs) 2002-05-15
WO2000073279A1 (en) 2000-12-07
GC0000191A (en) 2006-03-29
EP1187815B1 (de) 2006-02-08
BR0011127A (pt) 2002-02-19
NZ515407A (en) 2004-03-26
NO20015700L (no) 2001-11-22
ZA200109163B (en) 2003-02-06
TW550258B (en) 2003-09-01
JP2003500478A (ja) 2003-01-07
JO2261B1 (en) 2004-10-07
YU84901A (sh) 2004-09-03
KR20020000826A (ko) 2002-01-05
MXPA01012089A (es) 2002-06-04
HRP20010871A2 (en) 2003-04-30
PL353441A1 (en) 2003-11-17
HK1046528B (zh) 2005-02-25
CA2375671A1 (en) 2000-12-07
MY122731A (en) 2006-04-29
MA26793A1 (fr) 2004-12-20
CN1353697A (zh) 2002-06-12
AR024146A1 (es) 2002-09-04
DE60025918T2 (de) 2006-09-28
RU2243221C2 (ru) 2004-12-27
HUP0201315A2 (hu) 2002-12-28
CO5170520A1 (es) 2002-06-27
DK1187815T3 (da) 2006-06-19
IL146460A (en) 2006-10-31
NO20015700D0 (no) 2001-11-22
IL146460A0 (en) 2002-07-25
AU770786B2 (en) 2004-03-04
ES2257294T3 (es) 2006-08-01
HUP0201315A3 (en) 2003-02-28
CA2375671C (en) 2009-08-25
PT1187815E (pt) 2006-06-30
KR100440106B1 (ko) 2004-07-14

Similar Documents

Publication Publication Date Title
DE60009147D1 (de) Admantan derivate
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077L (no) Amino-triazolopyridin-derivater
DE50010060D1 (de) Thiazolylamid-derivate
ATE263748T1 (de) Admantan-derivate
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
DE60105020D1 (de) 6-phenylpyrrolopyrimidindion derivate
ATE257148T1 (de) Propargyletherderivate
DK1154988T3 (da) Mevinolinderivater
ATE374747T1 (de) Monofluoralkylderivate
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
ATE293592T1 (de) Resorcinderivate
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE230405T1 (de) 2-phenylpyran-4-one derivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20020212D0 (no) 3-amino-2-benzyl-1-fenyl-propanderivater
PT1194401E (pt) Derivados de diacil-hidrazina
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
ATE496034T1 (de) Phtalazinon derivate
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
DE60103859D1 (de) 2-phenylpyran-4-on derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187815

Country of ref document: EP

REN Ceased due to non-payment of the annual fee